摘要
Objective: To explore the therapeutic effect of montelukast sodium + methylprednisolone+ azithromycin therapy for patients with mycoplasma pneumonia. Methods: A total of 88 patients with mycoplasma pneumonia who were treated in our hospital between July 2015 and June 2017 were collected and divided into group A (oral azithromycin), group B (oral azithromycin + methylprednisolone), group C (oral azithromycin + montelukast sodium) and group D (oral montelukast sodium + methylprednisolone + azithromycin), and they were continuously treated for 1 week. The differences in therapeutic effect, systemic inflammatory response and stress response were compared among the four groups of patients. Results:After 1 week of treatment, the overall response rate of group D was higher than that of group A, group B and group C, and the overall response rate of group B and group C were higher than that of group A respectively;serum inflammatory factors C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor α (TNF-α), cortisol (COR), malondialdehyde (MDA) and advanced oxidation protein product (AOPP) levels of group D were lower than those of group A, group B and group C, and serum CRP, IL-6, TNF-α, COR, MDA and AOPP levels of group B and group C were lower than those of group A respectively. Conclusion:Montelukast sodium + methylprednisolone + azithromycin therapy can significantly improve the therapeutic effect and inhibit the systemic inflammatory and stress response in patients with mycoplasma pneumonia.
